ACTICOR BIOTECH: Presentation of Positive Results From the ACTIMIS Phase 1b/2a Study in Stroke at ESOC 2022
09 Mai 2022 - 06:05PM
Business Wire
Regulatory News:
ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT), a clinical-stage
biotechnology company developing an innovative drug for the
treatment of cardiovascular emergencies, announces today the
presentation of positive results from the Phase 1b/2a study,
ACTIMIS, in the treatment of acute ischemic stroke, at the 8th
European Stroke Organisation Conference (ESOC) on Friday May 6,
2022.
On this occasion, Professor Mikael Mazighi, MD, PhD,
Coordinating Investigator for ACTIMIS, presented the results of the
ACTIMIS study during the "Closing Ceremony & Large Clinical
Trials 2”:
Glenzocimab, a Novel Antithrombotic, is Associated with
Reduced Intracranial Hemorrhage and Mortality Rates when Combined
with Standard-Of-Care Reperfusion Therapies: The ACTIMIS
Study1
Find the exchanges during the ESOC with Professor Mikael
Mazighi: The media presentation The question-and-answer session
The positive results of the ACTIMIS phase 1b/2a study were
presented on February 22, 2022 (link to the press release).
About ESOC
The European Stroke Organisation (ESO) is a pan-European society
of stroke researchers and physicians, national and regional stroke
societies and lay organisations that was founded in December 2007.
The ESO is an NGO comprised of individual and organisational
members.
The aim of the ESO is to reduce the burden of stroke by changing
the way that stroke is viewed and treated. This can only be
achieved by professional and public education and making
institutional changes. ESO serves as the voice of stroke in Europe,
harmonising stroke management across the whole of Europe and taking
action to reduce the burden of stroke regionally and globally.
The 8th conference of the European Stroke Organisation took
place on May 4, 5 and 6, 2002 in Lyon.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
Acticor Biotech is developing glenzocimab (ACT017), a humanized
monoclonal antibody (mAb) fragment directed against a novel target
of major interest, platelet glycoprotein VI (GPVI). Glenzocimab
inhibits platelet binding to the thrombus without affecting
physiological hemostasis, thereby limiting the bleeding risk,
particularly in the brain.
Acticor Biotech is supported by a panel of European and
international investors (Karista, Go Capital, Newton Biocapital,
CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited,
Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum
farmaceutici and the Armesa foundation). Acticor Biotech is listed
on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 –
ALACT).
For further information, please go to
www.acticor-biotech.com
1 ESOC 2022 – late breaking science, ongoing trials & young
stroke physicians and researchers - Abstract #1758- GLENZOCIMAB, A
NOVEL ANTITHROMBOTIC, IS ASSOCIATED WITH REDUCED INTRACRANIAL
HEMORRHAGE AND MORTALITY RATES WHEN COMBINED WITH STANDARD-OF-CARE
REPERFUSION THERAPIES: THE ACTIMIS STUDY. European Stroke Journal
7, p574 (2022).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220509005836/en/
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD General Manager and CSO
Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN / Olivier BRICAUD Investor
Relations acticor@newcap.eu T. : +33 (0)1 44 71 94 95
Acticor Biotech (EU:ALACT)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Acticor Biotech (EU:ALACT)
Historical Stock Chart
Von Mär 2023 bis Mär 2024